CONSULT LHASA LIMITED
Consult Lhasa is a UK-based pharmaceutical scientific consultancy, wholly owned by Lhasa Limited, providing expert-led impurity, nitrosamine, extractables/leachables, and HBEL risk assessments for enterprise pharma clients using proprietary in silico toxicology platforms.
- Company typePrivate
- Founded2024
- HeadquartersLeeds, United Kingdom
- Headcount1–10
- GTM typeB2B
- OfferingServices
What CONSULT LHASA LIMITED does
Consult Lhasa Limited is a UK-based scientific consultancy specializing in impurity-related risk assessments for the pharmaceutical industry. Incorporated in January 2024 and headquartered in Leeds, the firm operates as a wholly-owned subsidiary of Lhasa Limited, a not-for-profit charity with more than 40 years of experience in computational chemistry and toxicology. Consult Lhasa translates Lhasa's proprietary in silico platforms—including Derek Nexus, Sarah Nexus, Vitic, Zeneth, and Mirabilis—into expert-led assessments covering potentially mutagenic impurities, nitrosamines, extractables and leachables (E&L), non-mutagenic impurities, and Health-Based Exposure Limits (HBELs).
The company's service portfolio addresses regulated pharmaceutical risk questions across drug development, manufacturing, and lifecycle management, helping sponsors navigate ICH M7, FDA, and EMA impurity and nitrosamine guidance. Consult Lhasa operates as a professional services business with a small team (1-10 employees as of latest data, expanded approximately 60% in 2025) and reinvests profits into its parent charity's scientific research mission. It offers multilingual consulting in seven-plus languages, free 30-minute expert consultations for prospective clients, and conducts active business development through conferences in Brazil, Mexico, China, South Korea, and India.
In December 2025, Consult Lhasa acquired Spektra Consultoria, a Brazilian regulatory consultancy, marking its first international expansion and entry into Latin America. The combined business serves enterprise pharmaceutical clients including Triquim, Laurus Labs Limited, and Rontis Hellas, and is led by CEO Dr Crina Heghes, who has been with Lhasa since 2012. No public revenue figures or external funding rounds are disclosed; growth has been funded internally by the parent charity.
CONSULT LHASA LIMITED firmographics
Firmographics- Name
- CONSULT LHASA LIMITED
- Legal name
- Consult Lhasa Limited
- Website
- https://consultlhasa.com
- Company type
- Private
- Founded year
- 2024
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Consult Lhasa is a UK-based pharmaceutical scientific consultancy, wholly owned by Lhasa Limited, providing expert-led impurity, nitrosamine, extractables/leachables, and HBEL risk assessments for enterprise pharma clients using proprietary in silico toxicology platforms.
- Ownership category
- akta.pro rank
CONSULT LHASA LIMITED industry classification
Industry- Product category
- Pharmaceutical Regulatory Consulting
- NAICS
- Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- In Silico / Computational Toxicology & PK/PD Modeling (HLAGAFAM)
- akta.pro secondary industries
- Genetic Toxicology (Ames/Micronucleus/Comet) (HLAGAFAE), Toxicology & Safety Assessment CROs (GLP) (HLAGAAAC), Extractables & Leachables / Container-Closure Testing (HLAGADAI)
Keywords
Where CONSULT LHASA LIMITED is headquartered
LocationHeadquarters
- HQ city
- Leeds
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
CONSULT LHASA LIMITED business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Scientific Risk Assessment Consulting: Consult Lhasa provides expert scientific risk assessment consulting services to the pharmaceutical industry, including impurity formation assessments, potentially mutagenic impurity assessments, nitrosamine risk assessments, and non-mutagenic impurity assessments. All proceeds are reinvested into Lhasa Limited for future scientific advancements.
- Extractables and Leachables Consulting: Newly launched E&L consulting service supporting robust, science-based justification throughout the E&L lifecycle, from study design through interpretation.
- Health-Based Exposure Limits (HBEL) Service: HBEL service provides structured scientific evaluation of pharmacological and toxicological data to define health-based exposure limits for products manufactured in shared facilities.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Free expert consultation |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels5 records
CONSULT LHASA LIMITED product offering
Product offeringCore offering
Consult Lhasa provides expert scientific risk assessment consultancy to pharmaceutical manufacturers, delivering structured, reproducible outputs for impurity formation, potentially mutagenic impurities, nitrosamines, non-mutagenic impurities, extractables and leachables, and health-based exposure limits. Assessments combine senior scientific consultants with proprietary in silico tools and curated toxicology databases developed by parent Lhasa Limited, aligning outputs to ICH Q3A/Q3B/Q3C/Q3D/Q3E and ICH M7 frameworks to support global regulatory submissions. All proceeds are reinvested into Lhasa Limited for further scientific research.
Product overview
Consult Lhasa is a Lhasa Limited subsidiary that delivers expert scientific risk assessment consultancy services to the pharmaceutical industry, combining Lhasa Limited software tools with expert scientific knowledge for regulatory submissions. Its core service portfolio spans five key risk assessment areas: Impurity Formation Risk Assessment, Potentially Mutagenic Impurities (PMI) Risk Assessment, Extractables and Leachables (E&L) Risk Assessment, Nitrosamine Risk Assessment, and Non-Mutagenic Impurities Risk Assessment. Additional services include a Health-Based Exposure Limits (HBELs) Service. The company was launched in January 2024 and expanded in 2025 through the acquisition of Spektra Consultoria (a Brazil-based toxicology consultancy). All Consult Lhasa proceeds are reinvested into Lhasa Limited for future scientific advancements.
Differentiator
Problem solved
Functional benefit
Products and services
- Impurity Formation Risk Assessment Expert risk assessments for impurity formation in active pharmaceutical ingredients (APIs) and drug products, supporting the definition of impurity profiles including API degradation, drug-excipient compatibility, synthesis impurity carry-over, and purge calculations. For pharmaceutical companies needing defensible impurity profiles for regulatory submissions.
- Potentially Mutagenic Impurities (PMI) Risk Assessment Computational toxicology assessment of potentially mutagenic impurities under ICH M7, using (Q)SAR methodologies (Derek Nexus and Sarah Nexus) with expert review to classify impurities and define acceptable limits and control strategies. For pharmaceutical regulatory and CMC teams.
- Extractables and Leachables (E&L) Risk Assessment Expert extractables and leachables risk assessments supporting patient safety, product quality, and regulatory compliance under the draft ICH Q3E guideline, including theoretical extractables review, safety threshold application, acceptable exposure level derivation, and read-across justification. For pharmaceutical packaging and container-closure stakeholders.
- Nitrosamine Risk Assessment Comprehensive nitrosamine risk assessments covering formation pathways in API synthesis and drug product, surrogate selection, acceptable intake (AI) calculation, and mechanistic docking evidence for nitrosamine activation, in line with ICH M7 and global regulatory guidance. For pharmaceutical manufacturers addressing nitrosamine impurities.
- Non-Mutagenic Impurities Risk Assessment Expert risk assessments for non-mutagenic impurities and cross-contaminants, including impurity qualification (weight-of-evidence assessments, safe limit derivation), residual solvents (PDE risk assessments), elemental impurities (ICH Q3D), and health-based exposure limits (HBELs/PDE/TTC) for shared facility cross-contamination evaluation. For pharmaceutical manufacturers needing non-mutagenic impurity qualification.
- Health-Based Exposure Limits (HBELs) Service Structured scientific evaluation of pharmacological and toxicological data to define a health-based exposure limit for a product manufactured in shared facilities, providing threshold values such as permitted daily exposure (PDE) or threshold of toxicological concern (TTC) for cross-contamination risk management. For pharmaceutical manufacturers operating shared production facilities.
- Spektra Consultoria Brazil-based toxicology consultancy integrated into Consult Lhasa following acquisition in December 2025, providing local regulatory expertise for Brazilian Health Regulatory Agency (Anvisa) submissions. For pharmaceutical companies submitting to Brazilian regulators.
Quantifiable outcome
- Delivered twice as many projects in 2025 compared to 2024
- +1 more outcomes
Companies that use CONSULT LHASA LIMITED
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles2 records
CONSULT LHASA LIMITED technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
CONSULT LHASA LIMITED partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Spektra ConsultoriacoreConsult Lhasa acquired Spektra Consultoria, a Brazil-based toxicology consultancy with strong record of Brazilian Health Regulatory Agency (Anvisa) acceptance. Spektra has submitted over 1,000 projects with 100% success rate. The acquisition integrates Spektra's local expertise with Consult Lhasa's global knowledge and resources, delivering enhanced value to clients in Brazil and those submitting to Brazilian regulators.
- Lhasa LimitedcoreConsult Lhasa is a wholly owned subsidiary of Lhasa Limited, a not-for-profit charity. All Consult Lhasa proceeds are reinvested into Lhasa Limited for future scientific advancements. Consult Lhasa utilizes Lhasa software and knowledge to provide scientific risk assessments. Lhasa Limited has over 40 years of collaboration with industry and regulatory authorities.
Scale indicators8 records
Recent moves8 records
Expansion highlights5 records
CONSULT LHASA LIMITED competitors and assessment
Company assessmentBroad incumbents
- Charles River Laboratories: Large CRO offering a broad portfolio including safety assessment, genetic toxicology, and impurity services for pharma. Comparable because it competes in the same end-to-end impurity/genotoxicity/E&L advisory market Consult Lhasa targets, but as part of a much wider preclinical and manufacturing portfolio.
- Labcorp Drug Development: Global CRO with comprehensive preclinical, bioanalytical, and central lab services including genotoxicity and impurity testing. Comparable because it serves the same pharma regulatory compliance buyers, though as a broad incumbent rather than a specialist in silico consultancy.
- Eurofins Scientific: Global testing group with extensive pharma services including extractables & leachables, genotoxicity, and regulatory-related testing. Comparable as a large incumbent offering adjacent impurity/E&L laboratory and consulting capabilities, though not a specialist in silico toxicology firm.
- Cyprotex (Evotec): Provider of in silico and in vitro ADME/tox services, now part of Evotec. Comparable because it offers computational toxicology and expert risk assessment work relevant to impurity profiling and safety qualification Consult Lhasa performs.
- Intertek: Global quality assurance provider offering pharmaceutical services including extractables & leachables, impurity, and regulatory-related testing. Comparable as a broad incumbent operating in some of the same regulatory compliance service lines.
Direct peers
- Simulations Plus: Provider of in silico ADME/tox modeling software and services (e.g., ADMET Predictor, DDI). Comparable because it offers computational toxicology and PBPK modeling that overlaps with Consult Lhasa's in silico impurity, mutagenicity, and exposure-limit work.
- MultiCASE: Provider of QSAR and expert-rule-based software (CASE Ultra) for toxicology and regulatory risk assessment. Comparable because its tools are direct alternatives to Lhasa's Derek Nexus / Sarah Nexus for ICH M7 impurity classification.
- Toxys: Netherlands-based provider of in vitro and in silico toxicology testing and consulting services for pharma and chemicals. Comparable because it combines computational toxicology (e.g., QSAR, mechanistic read-across) with expert risk assessment deliverables for impurity, genotoxicity, and safety evaluation.
- Instem (Leadscope): Provider of in silico toxicology and QSAR software (Leadscope) plus related scientific services for pharmaceutical regulatory submissions. Comparable because it serves the same (Q)SAR-based impurity and genotoxicity assessment workflow that Consult Lhasa performs using Derek/Sarah Nexus.
Emerging players
- Molecular Networks (Altair): Provider of computational chemistry software and services for chemical safety, including impurity profiling and in silico prediction tools. Comparable because it targets similar pharma regulatory use cases (ICH M7, impurities) with a smaller specialist footprint than global CROs.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
CONSULT LHASA LIMITED social profiles
Digital presenceCONSULT LHASA LIMITED compliance and trust
Trust signalCompliance6 records
CONSULT LHASA LIMITED financial estimates
Financial estimateRevenue estimate
Valuation estimate
CONSULT LHASA LIMITED leadership team
Management profileNumber of profiles
Profiles14 records
CONSULT LHASA LIMITED subsidiaries and ownership
Company hierarchySubsidiaries1 record
CONSULT LHASA LIMITED funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CONSULT LHASA LIMITED M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CONSULT LHASA LIMITED
What does CONSULT LHASA LIMITED do?
Consult Lhasa provides expert scientific risk assessment consultancy to pharmaceutical manufacturers, delivering structured, reproducible outputs for impurity formation, potentially mutagenic impurities, nitrosamines, non-mutagenic impurities, extractables and leachables, and health-based exposure limits. Assessments combine senior scientific consultants with proprietary in silico tools and curated toxicology databases developed by parent Lhasa Limited, aligning outputs to ICH Q3A/Q3B/Q3C/Q3D/Q3E and ICH M7 frameworks to support global regulatory submissions. All proceeds are reinvested into Lhasa Limited for further scientific research.
Is CONSULT LHASA LIMITED a public or private company?
CONSULT LHASA LIMITED is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was CONSULT LHASA LIMITED founded?
CONSULT LHASA LIMITED was founded in 2024. It employs 1 to 10 people.
Where is CONSULT LHASA LIMITED based?
CONSULT LHASA LIMITED is headquartered in Leeds, United Kingdom, in the Europe region.
How does CONSULT LHASA LIMITED make money?
Three revenue lines are on record. Scientific Risk Assessment Consulting is the primary driver. The others are extractables and Leachables Consulting and health-Based Exposure Limits (HBEL) Service.
Who are CONSULT LHASA LIMITED's main competitors?
Broad incumbents on record are Charles River Laboratories, Labcorp Drug Development, Eurofins Scientific, Cyprotex (Evotec) and Intertek. Direct peers are Simulations Plus, MultiCASE, Toxys and Instem (Leadscope). Molecular Networks (Altair) is listed as an emerging player.
Does CONSULT LHASA LIMITED have an API?
No public API is recorded for CONSULT LHASA LIMITED.
What industry is CONSULT LHASA LIMITED in?
CONSULT LHASA LIMITED's product category is Pharmaceutical Regulatory Consulting. Its primary akta.pro industry code is HLAGAFAM, In Silico / Computational Toxicology & PK/PD Modeling, with a secondary code of HLAGAFAE, Genetic Toxicology (Ames/Micronucleus/Comet). Its NAICS code is 5417 and its SIC code is 8731.